3-Hydroxypyridin-2-one | 125757-81-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-Hydroxypyridin-2-one
• 英文别名: 1-ethyl-3-hydroxypyridin-4-one
• CAS: 125757-81-5；99110-81-3
• 化学式: C₇H₉NO₂
• 分子量: 139.15
• InChiKey: KSFQNMZAJKFRIO-UHFFFAOYSA-N

物化性质

• 沸点：
  262.2±40.0 °C(Predicted)
• 密度：
  1.198±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS<br/>[FR] LIGANDS DE PROTÉINE D'ACTIVATION DES FIBROBLASTES POUR APPLICATIONS D'ADMINISTRATION CIBLÉE
  申请人：PHILOCHEM AG

  公开号：WO2021160825A1

  公开（公告）日：2021-08-19

  The present invention relates to ligands of Fibroblast Activation Protein (FAP) for the active delivery of various payloads (e.g. cytotoxic drugs, radionuclides, fluorophores, proteins and immunomodulators) at the site of disease. In particular, the present invention relates to the development of FAP ligands for targeting applications, in particular diagnostic methods and/or methods for therapy or surgery in relation to a disease or disorder, such as cancer, inflammation or another disease characterized by overexpression of FAP.

  本发明涉及纤维母细胞活化蛋白（FAP）的配体，用于在疾病部位主动传递各种有效载荷（例如细胞毒药物、放射性核素、荧光染料、蛋白质和免疫调节剂）。具体而言，本发明涉及开发用于靶向应用的FAP配体，特别是用于诊断方法和/或与疾病或疾病相关的治疗或手术方法，如癌症、炎症或另一种以FAP过表达为特征的疾病。
• Pharmaceutical compositions containing a complex of iron with N-substituted 3-hydroxypyrid-2-one or -4-one derivatives
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0094149A2

  公开（公告）日：1983-11-16

  Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic hydrocarbon group and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are also replaced by an aliphatic hydrocarbon group, are of value for the treatment of iron deficiency anaemia.

  含有 3-羟基吡啶-2-酮或 3-羟基吡啶-4-酮铁络合物的药物组合物，其中氮原子上的氢原子被脂肪族烃基取代，环碳原子上的一个或多个氢原子也被脂肪族烃基取代，具有治疗缺铁性贫血症的价值。
• Hydroxypyridone derivatives and pharmaceutical compositions containing them
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0138421A2

  公开（公告）日：1985-04-24

  Compounds in which two or more rings, being a 3-hydroxpy- pyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxpyrid-2-one, are linked are of value in the treatment of patients having a toxic concentration of a metal, particularly iron, in the body whilst the iron complexes of such compounds are of value in the treatment of iron deficiency anaemia.

  两个或两个以上环（3-羟基吡啶-2-酮、3-羟基吡啶-4-酮或 1-羟基吡啶-2-酮）相连的化合物对治疗体内金属（尤其是铁）浓度过高的病人很有价值，而此类化合物的铁络合物对治疗缺铁性贫血症很有价值。
• Pharmaceutical compositions containing N-substituted-3-hydroxypyrid-2-one or -4-one derivatives
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0093498B1

  公开（公告）日：1986-11-26
• FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS
  申请人：Philochem AG

  公开号：EP3891138B1

  公开（公告）日：2022-01-12